Guizhou Sanli Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of pharmaceuticals. The products primarily include respiratory medications, tonics, gynecological medications, orthopedic medications, and cardiovascular medications. The specific pharmaceutical products include Kaihoujian Spray (children's version), Kaihoujian Spray, Qijiao Shengbai Capsules, Fuke Zaizao Pills, Zhike Huatan Pills, Huangqi Granules, and Qiangli Tianma Duzhong Capsules. The Company distributes its products within the domestic market.

Employees

1,887

Sector

Pharmaceuticals

Calendar

10-28 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
30/09/26	CN¥13.18	-2.08%	10,006,600
29/09/26	CN¥13.46	+0.15%	10,598,300
28/09/26	CN¥13.44	-0.30%	14,287,981
24/09/26	CN¥13.48	-2.88%	11,863,700
23/09/26	CN¥13.88	-4.01%	15,080,324

End-of-day quote Shanghai S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. 30/09/2026			5-day change	1st Jan Change
13.18 ^CNY	-2.08%		-2.23%	+12.65%

08-27	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT

Market Cap	5.33B 796M 707M 660M 601M 1.13B 76.49B 1.14B 7.98B 3.09B 39.1B 2.99B 2.92B 125B	P/E 2024	19.4x	P/E 2025	106x
Enterprise Value	5.68B 848M 753M 703M 641M 1.21B 81.48B 1.22B 8.51B 3.3B 41.66B 3.18B 3.11B 134B	EV / Sales 2024	2.48x	EV / Sales 2025	2.99x
Free-Float	40.62%	Yield 2024	2.62%	Yield 2025	0.51%

08-27	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE
05-24	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 700 million in funding	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 30, 2026	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 300 million in funding	CI
12-03	Sanli Pharma to Withdraw Stake in Associate; Shares Down 3%	MT
27/10/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
12/09/25	Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on September 13, 2024.	CI
10/09/25	Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on September 12, 2024, has closed with 7,869,300 shares, representing 1.93% for CNY 99.95 million.	CI
27/08/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI

1 day	-2.08%
1 week	-2.23%
1 month	+9.02%
3 months	-2.30%
6 months	+16.23%
Current year	+12.65%

GuiZhou SanLi Pharmaceutical Co.,Ltd Share Price

Stocks

603439

CNE1000040B4

Pharmaceuticals

Valuation: GuiZhou SanLi Pharmaceutical Co.,Ltd

Chart: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest news: GuiZhou SanLi Pharmaceutical Co.,Ltd

Quotes and Performance

Price Extremes

Managers and Directors: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	13.12	13.77
1 month	10.91	15.17
Current year	9.51	17.46
1 year	9.51	17.46
3 years	9.51	20.34
5 years	9.51	21.28
10 years	8.82	44.1

Manager	Title	Age	Since
Qian Fan Zhang CEO	Chief Executive Officer	41	26/05/2024
Hai Zhang CEO	Chief Executive Officer	41	31/08/2011
Ke Guo DFI	Director of Finance/CFO	39	31/10/2024

Director	Title	Age	Since
Hai Zhang CHM	Chairman	41	28/02/2018
Qian Fan Zhang BRD	Director/Board Member	41	28/02/2018
Yong Jian Sheng BRD	Director/Board Member	52	27/01/2015

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/09/24	Hai Zhang	Sell	Chief Executive Officer	21,000,000	5.1428%
02/08/24	Jue Ben Wang	Buy	Director	13,000	0.0032%
05/08/23	Yuan Yu	Sell		25,000	0.0061%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU SANLI PHARMACEUTICAL CO.,LTD	-2.08%	-2.23%	+4.19%	-25.96%	795M
ELI LILLY AND COMPANY	-0.31%	-3.07%	+39.92%	+113.11%	1,025B
JOHNSON & JOHNSON	-1.27%	-5.88%	+37.26%	+64.53%	623B
ABBVIE INC.	+1.20%	-0.51%	+11.17%	+77.40%	459B
MERCK & CO., INC.	+0.04%	-3.27%	+60.79%	+40.34%	355B
ROCHE HOLDING AG	-0.95%	-4.05%	+21.60%	+39.37%	336B
NOVARTIS AG	-1.46%	-2.89%	+11.84%	+24.60%	270B
ASTRAZENECA PLC	-1.35%	-5.43%	-4.69%	+8.40%	247B
AMGEN INC.	-0.82%	-2.50%	+35.93%	+51.80%	220B
GILEAD SCIENCES, INC.	-1.93%	-4.35%	+30.57%	+94.82%	183B
Average	-0.93%	-2.21%	+24.86%	+48.84%	371.9B
Weighted average by Cap.	-0.59%	-2.11%	+30.56%	+69.02%

	2024	2025
Net sales	2.14B 320M 284M 265M 242M 456M 30.75B 460M 3.21B 1.24B 15.72B 1.2B 1.17B 50.44B	1.7B 254M 226M 211M 192M 362M 24.42B 365M 2.55B 988M 12.48B 954M 933M 40.06B
Net income	274M 40.87M 36.31M 33.89M 30.89M 58.26M 3.93B 58.8M 410M 159M 2.01B 153M 150M 6.45B	46.25M 6.9M 6.13M 5.72M 5.21M 9.83M 663M 9.93M 69.23M 26.83M 339M 25.9M 25.34M 1.09B
Net Debt	108M 16.06M 14.27M 13.32M 12.14M 22.89M 1.54B 23.1M 161M 62.45M 789M 60.29M 58.98M 2.53B	349M 52.01M 46.21M 43.13M 39.31M 74.14M 5B 74.83M 522M 202M 2.56B 195M 191M 8.2B